Despite the emergence of immune checkpoint blockade as a promising new treatment for cancers, a majority of cancer patients, including pancreatic cancer patients, do not benefit from monotherapy with PD-L1 or CTLA-4 blockade [1, 2]. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.